Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma : vimarsana.com

The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.

Related Keywords

China , Peking , Beijing , Jun Guo , National Medical Products Administration Of China , Shanghai Junshi Biosciences Co Ltd , University Cancer Hospital , International Metastatic Renal Cell Carcinoma Database Consortium , National Medical Products Administration , Peking University Cancer Hospital , News , Global Oncology , Immuno Oncology , Genitourinary Cancers , Toripalimab Plus Axitinib , First Line Treatment Of Patients With Medium To High Risk Unresectable Or Metastatic Rcc , The National Medical Products Administration Of China ,